Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas J Short

Showing results (1-10 of 346) with videos related to

Pageof 35
Sort By:
Haematologica|July 6, 2019
How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?Nicholas J Short, Farhad Ravandi
The Lancet. Haematology|April 1, 2023
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the pastNicholas J Short, Hagop Kantarjian
Clinical Advances in Hematology & Oncology : H&O|December 9, 2016
Should treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia be intensive? Intensive treatment is the best treatment for these patientsNicholas J Short, Elias Jabbour
Current Oncology Reports|February 17, 2017
Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat ItNicholas J Short, Elias Jabbour
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Acute Myeloid Leukemia: Past, Present, and Prospects for the FutureNicholas J Short, Farhad Ravandi
The Lancet. Haematology|March 31, 2019
10-day vs 5-day decitabine: equivalence cannot be concluded - Authors' replyNicholas J Short, Farhad Ravandi
Current Oncology Reports|February 10, 2022
Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and ManagementShilpa Paul, Nicholas J Short
American Journal of Hematology|September 25, 2024
Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug developmentNicholas J Short, Richard Dillon
Clinical Advances in Hematology & Oncology : H&O|July 28, 2017
Yes, treatment for CML should continue indefinitelyNicholas J Short, Elias Jabbour
Acta Haematologica|July 29, 2025
Advances in Acute Lymphoblastic Leukemia Review SeriesJayastu Senapati, Nicholas J Short
Pageof 35

Showing results (1-10 of 346) with videos related to

Sort By:
Pageof 35
Haematologica|July 6, 2019
How close are we to incorporating measurable residual disease into clinical practice for acute myeloid leukemia?Nicholas J Short, Farhad Ravandi
The Lancet. Haematology|April 1, 2023
Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the pastNicholas J Short, Hagop Kantarjian
Clinical Advances in Hematology & Oncology : H&O|December 9, 2016
Should treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia be intensive? Intensive treatment is the best treatment for these patientsNicholas J Short, Elias Jabbour
Current Oncology Reports|February 17, 2017
Minimal Residual Disease in Acute Lymphoblastic Leukemia: How to Recognize and Treat ItNicholas J Short, Elias Jabbour
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Acute Myeloid Leukemia: Past, Present, and Prospects for the FutureNicholas J Short, Farhad Ravandi
The Lancet. Haematology|March 31, 2019
10-day vs 5-day decitabine: equivalence cannot be concluded - Authors' replyNicholas J Short, Farhad Ravandi
Current Oncology Reports|February 10, 2022
Central Nervous System Involvement in Adults with Acute Leukemia: Diagnosis, Prevention, and ManagementShilpa Paul, Nicholas J Short
American Journal of Hematology|September 25, 2024
Measurable residual disease monitoring in AML: Prospects for therapeutic decision-making and new drug developmentNicholas J Short, Richard Dillon
Clinical Advances in Hematology & Oncology : H&O|July 28, 2017
Yes, treatment for CML should continue indefinitelyNicholas J Short, Elias Jabbour
Acta Haematologica|July 29, 2025
Advances in Acute Lymphoblastic Leukemia Review SeriesJayastu Senapati, Nicholas J Short
Pageof 35